Baxter files BAX 326 at FDA for management of Haemophilia B

Baxter has announced that the company has submitted a biologics license application (BLA) to the FDA for approval of BAX 326, a recombinant factor IX (rFIX) protein being investigated for the treatment and prophylaxis of bleeding episodes for patients over 12 years of age with Haemophilia B. Haemophilia B, also known as Christmas disease, is the second most common type of hemophilia and results from insufficient amounts of clotting factor IX, a naturally occurring protein in blood that helps to control bleeding.